RBE Cell Line

Brief Introduction
Product List

General Information
Organism	Homo sapiens. human
Cell Line Description	RBE is a human intrahepatic cholangiocarcinoma (ICC) cell line established by M. Enjoji, M. Entani, and their colleagues in 1997. The cell line was isolated from the primary tumor of a 64-year-old Asian female patient with intrahepatic cholangiocarcinoma (a type of biliary tract cancer). RBE cells exhibit an epithelial-like morphology and grow as an adherent monolayer. In the fields of hepatobiliary oncology, gastroenterology, and pharmacology, RBE is recognized as a premier and foundational in vitro model for studying intrahepatic cholangiocarcinoma (ICC). It provides a vital platform for investigating the mechanisms of invasion in biliary tract cancer, elucidating the KRAS/MAPK oncogenic signaling network, assessing mechanisms of chemoresistance to gemcitabine and cisplatin, and testing targeted therapies for primary liver and bile duct malignancies.
Tissue	Liver / Bile Duct; derived from Intrahepatic Bile Duct
Cell Type	Epithelial cell (Cholangiocyte / Biliary Epithelium)
Population / Ancestry	Asian
Disease	Intrahepatic Cholangiocarcinoma (ICC) / Biliary Tract Cancer
Morphology	Epithelial-like; polygonal cells growing in cohesive monolayer sheets
Gender	Female
Age	64 years
Product Format	Frozen
Growth Mode	Adherent
Biosafety Level	1 (Biosafety classification matches standard international guidelines for non-infectious human tumor cells)
Applications	1. A "gold-standard" in vitro model for studying the pathogenesis, cell migration, and extracellular matrix invasion of intrahepatic cholangiocarcinoma (ICC); 2. Elucidation of oncogenic signaling cascades driven by KRAS and TP53 mutations, as well as the downstream MEK/ERK and PI3K/AKT pathways; 3. High-throughput preclinical screening of novel chemotherapeutic agents, targeted kinase inhibitors, and combination immunotherapies; 4. Investigation of mechanisms underlying acquired resistance to first-line chemotherapy regimens (e.g., gemcitabine plus cisplatin) for biliary tract cancer; 5. Establishment of subcutaneous or orthotopic cholangiocarcinoma xenograft models derived from cell lines in immunodeficient mice.
Shipped In	Dry ice
Storage Temperature	−196°C
Characteristics
Tumorigenic	Yes, highly tumorigenic; forms rapidly growing, mucin-secreting cholangiocarcinomas when inoculated subcutaneously or orthotopically into athymic nude rodents.
Transformant	None; immortalized spontaneously from advanced primary intrahepatic cholangiocarcinoma tissue.
Oncogenic Driver & Key Mutations	1. KRAS status: Mutant; the KRAS gene harbors an activating missense mutation, p.Gly12Asp (c.35G>A). 2. TP53 status: Mutant; the TP53 tumor suppressor gene harbors an inactivating mutation. 3. Microsatellite status: Stable (MSS).
Expression Profile	Expresses biliary epithelial lineage markers, including Cytokeratin-7 (CK7), Cytokeratin-19 (CK19), and E-cadherin, as well as Carcinoembryonic Antigen (CEA).
Growth Kinetics	Robust adherent proliferation; typical population doubling time spans approximately 24 to 32 hours.
Mycoplasma Test	Negative
Culture Conditions and Handling
Subculturing	1. Completely aspirate and discard the complete culture medium from the culture vessel. 2. Gently wash the cell monolayer with sterile, Ca2+/Mg2+-free PBS to remove residual serum containing active trypsin inhibitors. 3. Add 1.0 to 2.5 mL of 0.25% trypsin-0.53 mM (0.02%) EDTA solution, pre-warmed to the appropriate temperature, ensuring the cell layer is completely covered. 4. Incubate at 37°C for 2 to 5 minutes; monitor under an inverted microscope until the cells become rounded, loosen, and completely detach. 5. Add an equal volume of complete growth medium, pre-warmed to the appropriate temperature, to immediately neutralize trypsin activity. 6. Gently pipette the cell suspension to disperse the cells, centrifuge at approximately 125 × g for 5 minutes, carefully discard the supernatant, gently resuspend the cells in fresh complete growth medium, and distribute them into new culture vessels.
Thawing Protocol Note	RBE cells are sensitive to pH changes during early post-thaw recovery. Prior to introducing thawed vial contents, place the culture vessel containing fresh complete growth medium into the 5% CO2 incubator for at least 15 minutes to allow the medium to equilibrate to its physiological pH range (7.0 to 7.6).
Medium Renewal	2 to 3 times per week
Subcultivation Ratio	Split confluent cultures (80% density) at a standard ratio of 1:3 to 1:6. Maintain active growth by subculturing before cells become 100% confluent.
Culture Conditions	Atmosphere: Air, 95%; CO2, 5%; Temperature: 37°C
Cryopreservation	90% Complete culture growth medium + 10% DMSO (or 50% RPMI 1640 + 40% FBS + 10% DMSO)

Cat.No.	Product Name	Price
CSC-RR00993	GFP/Luc Reporter Cell Line - RBE	Inquiry
CSC-RR01229	Nluc Reporter Cell Line - RBE	Inquiry

The above is only part of a part of cell line products. If you don't find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.

* For research use only. Not intended for any clinical use.

Quick Inquiry